Twenty years treating early-stage epithelial ovarian carcinoma patients with adjuvant platinum-based chemotherapy. A single institution’s experience

5167 Background: One-third of epithelial ovarian cancer (EOC) patients (pts) present with localized disease and have a 50–70% ten-year survival. Prognostic factors and adjuvant strategies have been explored. Platinum-based chemotherapy (QT) is the mainstay of therapy. Aims: To describe Disease-Free Survival (DFS) and Overall Survival (OS) in EOC stage I-II pts receiving adjuvant platinum-based QT at our institution in the last 20 years. To determine prognostic factors and the role of paclitaxel addition. Methods: Retrospective analysis including all incident early-stage EOC pts receiving adjuvant platinum-based QT from 1984 to 2003. Well differentiated FIGO stages I were excluded. Demographic-data, surgical procedures, histological features, toxicities, follow-up and outcome were recorded. Up to 1997 pts received QT: CDDP 80mg/m2-CTX 750mg/m2, CBDCA 300mg/m2-CTX 600mg/m2, CDDP 80mg/m2-ADM 50mg/m2-CTX 500 mg/m2, every 3–4 w x 6. From 1997: Paclitaxel 175 mg/m2 and CBDCA AUC5 every 3 w x 4–6. Results: 140 p...